



## **MERGER ANNOUNCEMENT     27 FEBRUARY 2014**

---

### **Competition Authority Clears Acquisition of sole control of Ortho Clinical Diagnostics by Crimson Bermuda Co. Ltd**

The Competition Authority has cleared the proposed acquisition of sole control of Ortho Clinical Diagnostics by Crimson Bermuda Co. Ltd. The transaction was notified under the Competition Act 2002 on 4 February 2014.

The Authority has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The companies have been informed of the decision. The Authority will publish a public version of the reasons for its determination on its website ([www.tca.ie](http://www.tca.ie)) no later than 26 April 2014 after allowing the parties the opportunity to request that confidential information is removed from the published version.

#### **Notes**

Crimson is controlled by funds managed by affiliates of Carlyle. Carlyle is a global asset fund manager investing across four business segments: (a) corporate private equity; (b) real assets; (c) global market strategies; and (d) global solutions. Carlyle companies active in the State are involved in sectors as diverse as the manufacture of consumer packaging, the manufacture and sale of vitamins, provision of motor insurance and network infrastructure.

OCD is a Johnson & Johnson business headquartered in New Jersey in the US. OCD provides in-vitro diagnostic systems, which include both the instruments in which the tests are performed ('analysers'); and the chemistry solutions necessary to perform the individual tests ('reagents/assays').

#### **For further information contact:**

**Clodagh Coffey**, Communications Manager, The Competition Authority  
Tel: 01 8045406                      Mobile: 087 915 5406                      email: [cc@tca.ie](mailto:cc@tca.ie)